How did BEAM's revenue and expenses shift in Q4 2023?
5/8/2025 00:41am
Beam Therapeutics (BEAM) exhibited consistent financial performance across its business segments in Q4 2023, with each segment reporting a net income of $142.8 million. The company's revenue was primarily generated from license agreements, totaling $316.19 million for the quarter.
|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|BEEM|BEEM.O|Beam|20231001-2023|Discounts and Allowances|-337000|186|
|BEEM|BEEM.O|Beam|20231001-2023|Discounts and Allowances|-337000|186|
|BEEM|BEEM.O|Beam|20231001-2023|Maintenance Fees|83000|186|
|BEEM|BEEM.O|Beam|20231001-2023|Product|6.5152E7|186|
|BEEM|BEEM.O|Beam|20231001-2023|Professional Services|146000|186|
|BEEM|BEEM.O|Beam|20231001-2023|Shipping and Handling|2308000|186|